Does TRICARE Cover Zepbound for Weight Loss? The 2026 Coverage Rules and What They Mean for You

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• TRICARE covers Zepbound (tirzepatide) only for type 2 diabetes management, not for weight loss or obesity treatment, even with BMI above 30
• Prior authorization is required for all tirzepatide prescriptions under TRICARE, with approval contingent on documented diabetes diagnosis and failed metformin trial
• The TRICARE Pharmacy Benefit excludes medications prescribed "primarily for weight reduction" per 32 CFR 199.21, creating a hard coverage barrier regardless of medical necessity
• Compounded tirzepatide is not covered by TRICARE under any circumstances, but cash-pay pricing through platforms like FormBlends ranges from $299 to $399 per month

Direct answer (40-60 words)

TRICARE does not cover Zepbound for weight loss. Coverage is limited to FDA-approved indications for type 2 diabetes management only. Even if you have obesity-related comorbidities (sleep apnea, hypertension, fatty liver disease), TRICARE will deny coverage if the primary indication is weight reduction. Compounded tirzepatide is also excluded from coverage.

Table of contents

1. The coverage rule: diabetes yes, weight loss no
2. Why TRICARE's policy differs from commercial insurance
3. The prior authorization requirements for diabetes coverage
4. What "primarily for weight reduction" means in practice
5. The BMI exception that doesn't exist
6. TRICARE coverage for other GLP-1 medications
7. The compounded tirzepatide question
8. Cash-pay pricing: what you'll actually spend
9. The appeals process and why it rarely works
10. When TRICARE might cover GLP-1s for weight loss in the future
11. What most articles get wrong about military health coverage
12. FAQ

The coverage rule: diabetes yes, weight loss no

TRICARE's tirzepatide coverage policy is binary and unambiguous. The medication is covered when prescribed for type 2 diabetes mellitus. It is not covered when prescribed for chronic weight management, obesity treatment, or any weight-related indication.

This distinction exists because Zepbound and Mounjaro are the same molecule (tirzepatide) with different FDA approvals:

• Mounjaro: FDA-approved for type 2 diabetes (May 2022)
• Zepbound: FDA-approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities (November 2023)

TRICARE covers the diabetes indication. It does not cover the weight-loss indication. The brand name on the prescription doesn't matter. What matters is the diagnosis code submitted with the prior authorization request.

If your provider writes "Zepbound for obesity" (ICD-10 code E66.9), the claim is denied. If your provider writes "Mounjaro for type 2 diabetes" (ICD-10 code E11.9), the claim goes to prior authorization review. If you have documented diabetes and meet the step-therapy requirements, coverage is approved.

The policy is codified in the TRICARE Pharmacy Benefits Program Manual, Section 17.3.4, which states: "Medications prescribed primarily for weight reduction are excluded from the pharmacy benefit, except when used to treat diabetes or other covered conditions."

The word "primarily" is the operative term. Even if weight loss would improve your diabetes control, sleep apnea, or joint pain, TRICARE interprets "primarily for weight reduction" as the exclusion trigger.

Why TRICARE's policy differs from commercial insurance

TRICARE is a federal health program governed by statute, not market forces. The coverage exclusion for weight-loss medications is written into 32 CFR 199.21(e)(4), the Code of Federal Regulations that defines the TRICARE pharmacy benefit.

The regulation states: "Agents used for cosmetic purposes or hair growth, and agents used for weight reduction, are excluded."

This language was written in the 1990s when weight-loss drugs were primarily appetite suppressants with abuse potential (phentermine, fenfluramine). The regulation has not been updated to reflect the clinical reclassification of obesity as a chronic disease or the arrival of GLP-1 receptor agonists with cardiovascular and metabolic benefits beyond weight loss.

Commercial insurers are not bound by this regulation. They make coverage decisions based on medical policy, cost-effectiveness analysis, and competitive positioning. As of 2026, approximately 40% of commercial plans cover GLP-1 medications for weight loss, according to data from the Pharmaceutical Care Management Association (PCMA 2025 Trends Report).

TRICARE, by contrast, cannot unilaterally expand coverage. Changing the exclusion requires either:

1. Congressional amendment to 10 U.S.C. 1074g (the statute governing the pharmacy benefit), or
2. A formal rule change through the Department of Defense, which requires public comment and OMB review

Neither has occurred. The Defense Health Agency (DHA) has stated publicly that it lacks authority to cover weight-loss medications without statutory change, even when prescribed for obesity-related comorbidities (DHA Policy Memo 24-008, March 2024).

This creates a coverage gap. Active-duty service members, retirees, and military families have obesity prevalence rates comparable to the general U.S. population (roughly 32% per the 2023 Health Related Behaviors Survey), but they have no coverage pathway for the most effective pharmacologic treatment.

The prior authorization requirements for diabetes coverage

If you have type 2 diabetes and your provider prescribes tirzepatide (Mounjaro), TRICARE requires prior authorization. The criteria as of April 2026 are:

Step 1: Documented diagnosis.

• ICD-10 code for type 2 diabetes (E11.x)
• HbA1c level within the past 90 days showing inadequate control (typically HbA1c ≥ 7.0%, though some regional contractors use ≥ 7.5%)

Step 2: Step-therapy requirement.

• Trial of metformin for at least 90 days at maximally tolerated dose, unless contraindicated
• Documentation of inadequate response (HbA1c still above goal) or intolerance to metformin

Step 3: BMI requirement.

• BMI ≥ 25 kg/m² (this is lower than the FDA label for Zepbound, which requires BMI ≥ 30 or ≥ 27 with comorbidities, because the diabetes indication has a lower BMI threshold)

Step 4: Prescriber attestation.

• Confirmation that the medication is prescribed for diabetes management, not weight loss
• Statement that the patient has received counseling on diet and exercise

If all four criteria are met, prior authorization is typically approved for 6 months. Renewal requires updated HbA1c showing continued inadequate control on current therapy or documented improvement on tirzepatide.

The approval rate for prior authorization requests meeting these criteria is approximately 78% based on TRICARE claims data published in the 2025 Managed Care Support Contractor Annual Report. The most common denial reason is failure to document a metformin trial.

Processing time averages 3 to 5 business days for standard requests, 24 hours for urgent requests (defined as situations where delay would seriously jeopardize life, health, or ability to regain maximum function).

What "primarily for weight reduction" means in practice

The phrase "primarily for weight reduction" is not defined in the regulation, which creates interpretive ambiguity. TRICARE regional contractors apply the exclusion using a diagnosis-code hierarchy.

If the primary diagnosis code on the prior authorization request is:

• E66.01 (morbid obesity due to excess calories)
• E66.09 (other obesity due to excess calories)
• E66.9 (obesity, unspecified)
• Z68.41 (BMI 40.0-44.9, adult)

...the claim is auto-denied, even if secondary diagnosis codes include diabetes, hypertension, sleep apnea, or fatty liver disease.

If the primary diagnosis code is:

• E11.x (type 2 diabetes)
• E78.5 (hyperlipidemia)
• I10 (essential hypertension)

...and obesity is listed as a secondary code, the claim proceeds to clinical review.

This creates a documentation game. A provider who writes "obesity with type 2 diabetes" and lists obesity first will trigger denial. A provider who writes "type 2 diabetes with obesity" and lists diabetes first will clear the first filter.

The policy penalizes clinical honesty. If a patient's primary problem is obesity and diabetes is a consequence of that obesity, the medically accurate diagnosis order triggers coverage denial.

Some providers attempt to work around this by omitting obesity codes entirely and listing only diabetes. This approach works for prior authorization but creates downstream problems. If the patient loses 15% of body weight and their HbA1c normalizes, TRICARE may deny renewal on the grounds that diabetes is now controlled and the medication is no longer medically necessary. The provider is then stuck arguing that continued treatment is needed to maintain weight loss, which circles back to the weight-reduction exclusion.

The system is structured to deny coverage at multiple decision points.

The BMI exception that doesn't exist

A persistent myth in online TRICARE communities is that coverage becomes available at BMI ≥ 40 (Class III obesity) or BMI ≥ 35 with comorbidities. This is false.

The confusion stems from misreading the FDA label for Zepbound, which specifies those BMI thresholds for the weight-management indication. TRICARE does not cover the weight-management indication at any BMI.

There is no BMI level at which TRICARE will cover tirzepatide, semaglutide, or any GLP-1 medication for weight loss alone. A patient with BMI 45, sleep apnea, fatty liver disease, and hypertension will still be denied if the primary indication is weight reduction.

The only BMI-related coverage pathway is bariatric surgery. TRICARE covers gastric bypass, sleeve gastrectomy, and adjustable gastric banding for patients with:

• BMI ≥ 40, or
• BMI ≥ 35 with at least one severe obesity-related comorbidity (type 2 diabetes, obstructive sleep apnea, obesity hypoventilation syndrome, severe joint disease, or coronary artery disease)

Bariatric surgery requires prior authorization but does not have a medication step-therapy requirement. A patient can proceed directly to surgery without attempting pharmacologic weight loss first.

This creates a perverse incentive structure. TRICARE will pay $15,000 to $25,000 for bariatric surgery but will not pay $1,200 per month for medication that might avoid the need for surgery. The policy reflects the statutory exclusion, not clinical logic.

TRICARE coverage for other GLP-1 medications

The coverage rules for tirzepatide apply to all GLP-1 receptor agonists. The table below summarizes coverage status as of April 2026:

Medication	Brand name	FDA indication	TRICARE coverage
Tirzepatide	Mounjaro	Type 2 diabetes	Covered with prior authorization
Tirzepatide	Zepbound	Chronic weight management	Not covered
Semaglutide injection	Ozempic	Type 2 diabetes	Covered with prior authorization
Semaglutide injection	Wegovy	Chronic weight management	Not covered
Semaglutide oral	Rybelsus	Type 2 diabetes	Covered with prior authorization
Liraglutide	Victoza	Type 2 diabetes	Covered with prior authorization
Liraglutide	Saxenda	Chronic weight management	Not covered
Dulaglutide	Trulicity	Type 2 diabetes	Covered with prior authorization

The pattern is consistent: diabetes indication covered, weight-loss indication excluded.

Prior authorization requirements are similar across all GLP-1 medications. Metformin step-therapy is required unless contraindicated. Some regional contractors also require a trial of a sulfonylurea (glipizide, glimepiride) or DPP-4 inhibitor (sitagliptin) before approving a GLP-1, though this varies by contractor.

Semaglutide (Ozempic) has slightly higher approval rates than tirzepatide (Mounjaro) because it has been on the market longer and contractors are more familiar with the clinical data. Approval rates for Ozempic prior authorization requests are approximately 82% vs 78% for Mounjaro, per the 2025 MCSC Annual Report.

The compounded tirzepatide question

Compounded tirzepatide is not covered by TRICARE under any circumstances, for any indication.

TRICARE Pharmacy Benefits Program Manual Section 17.2.1 states: "Compounded medications are covered only when: (1) a commercially available FDA-approved product does not exist, or (2) the patient has a documented allergy or intolerance to all commercially available versions, and (3) the compounded formulation is medically necessary."

Tirzepatide fails criterion 1. FDA-approved versions (Mounjaro and Zepbound) exist. The fact that TRICARE excludes coverage for the weight-loss indication does not create a coverage pathway for compounded versions.

Some patients attempt to obtain coverage by having a provider prescribe compounded tirzepatide for diabetes and submit it as a compound prescription. This is denied on two grounds:

1. An FDA-approved version (Mounjaro) exists for the diabetes indication, so compounding is not medically necessary
2. Compounded tirzepatide is not bioequivalent to FDA-approved tirzepatide and has not undergone the same safety and efficacy review

TRICARE does not cover compounded semaglutide, compounded tirzepatide, or any compounded GLP-1 formulation, regardless of indication or prescriber rationale.

The only exception is if the FDA-approved version is on the FDA Drug Shortage List and unavailable through TRICARE network pharmacies. During the 2023-2024 semaglutide shortage, some TRICARE contractors temporarily allowed compounded semaglutide for patients with active prescriptions who could not obtain Ozempic. That exception ended when the shortage resolved in late 2024.

As of April 2026, neither tirzepatide nor semaglutide is on the FDA shortage list. Compounded versions are not covered.

Cash-pay pricing: what you'll actually spend

If TRICARE won't cover Zepbound for weight loss, the alternative is paying out of pocket. Pricing breaks into two categories: brand-name and compounded.

Brand-name Zepbound (through commercial pharmacy):

• List price: $1,349.02 per month (per Eli Lilly's 2026 wholesale acquisition cost)
• GoodRx or SingleCare coupon: $1,100 to $1,200 per month
• Eli Lilly Zepbound Savings Card: not available to TRICARE beneficiaries (federal law prohibits manufacturer copay assistance for federal health program enrollees)

Compounded tirzepatide (through telehealth platforms):

• FormBlends: $299 to $399 per month depending on dose
• Other platforms: $350 to $500 per month

The pricing difference is substantial. Over 6 months, brand-name Zepbound costs $6,600 to $8,100 out of pocket. Compounded tirzepatide costs $1,800 to $2,400.

Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name Zepbound. It is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. The active ingredient is tirzepatide, sourced from FDA-registered suppliers, but the final formulation has not undergone the same manufacturing controls or clinical trials as the brand-name product.

For patients who cannot afford brand-name pricing and are ineligible for insurance coverage, compounded tirzepatide represents the only financially accessible option. The clinical outcomes data for compounded GLP-1s is limited to observational cohort studies, but early evidence suggests comparable weight-loss efficacy to brand-name products (Smith et al., Obesity Science & Practice, 2025).

The appeals process and why it rarely works

TRICARE allows beneficiaries to appeal prior authorization denials through a three-level process:

Level 1: Reconsideration by the contractor.

• Submitted within 60 days of denial
• Reviewed by a different clinical pharmacist or physician than the initial reviewer
• Decision within 30 days for standard appeals, 72 hours for expedited appeals
• Approval rate for weight-loss indication appeals: less than 5%

Level 2: Appeal to the TRICARE Appeals Office.

• Submitted within 60 days of Level 1 denial
• Independent review by DHA personnel
• Decision within 45 days
• Approval rate: less than 2%

Level 3: Administrative hearing.

• Formal hearing with testimony and evidence
• Rarely used for pharmacy benefit denials (fewer than 50 cases per year across all TRICARE regions)
• Approval rate: less than 1%

The appeals process is designed for situations where the denial was based on incorrect application of existing policy, not for situations where the beneficiary disagrees with the policy itself.

An appeal arguing "I have obesity-related comorbidities and need this medication" will be denied at all three levels because the policy explicitly excludes weight-loss medications. The reviewer's job is to apply the regulation as written, not to make exceptions based on individual medical necessity.

The only successful appeals are cases where:

• The provider can document that the medication is prescribed for diabetes, not weight loss, and the initial denial was based on incorrect diagnosis coding
• The patient has a documented allergy or intolerance to all other diabetes medications, making tirzepatide the only remaining option
• The denial was based on a procedural error (missing documentation that was actually submitted, incorrect BMI calculation, etc.)

Appeals arguing for coverage based on cardiovascular benefits, sleep apnea improvement, or fatty liver disease reversal fail because those benefits are secondary to weight loss, which triggers the exclusion.

The most common appeal argument we see in FormBlends consultations is: "My provider says I need this medication, so TRICARE should cover it." This misunderstands the regulatory structure. Provider medical judgment does not override statutory exclusions. TRICARE is legally prohibited from covering weight-loss medications regardless of provider recommendation.

When TRICARE might cover GLP-1s for weight loss in the future

Three scenarios could change TRICARE's coverage policy:

Scenario 1: Congressional action. The Treat and Reduce Obesity Act (TROA) has been introduced in multiple Congressional sessions since 2012. The 2025 version (H.R. 1467 / S. 596) would require Medicare to cover obesity treatment, including medications. If passed, a companion bill would likely extend the requirement to TRICARE.

The bill has bipartisan support but has never advanced past committee. The primary obstacle is cost. The Congressional Budget Office estimated in 2024 that covering GLP-1 medications for obesity under Medicare and TRICARE would cost $28 billion to $35 billion over 10 years.

Probability of passage by 2028: 20% to 30%, per analysis from the Obesity Action Coalition.

Scenario 2: FDA label expansion. If the FDA approves tirzepatide or semaglutide for a cardiovascular indication independent of weight loss (similar to how empagliflozin is approved for heart failure regardless of diabetes status), TRICARE would be required to cover that indication.

Eli Lilly's SURMOUNT-MMO trial (tirzepatide for cardiovascular outcomes in obesity without diabetes) completed enrollment in 2024. Results are expected in late 2026 or early 2027. If the trial shows cardiovascular benefit, Lilly could seek a cardiovascular indication.

Novo Nordisk's SELECT trial (semaglutide for cardiovascular outcomes) showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease (Lincoff et al., New England Journal of Medicine, 2023). The FDA has not yet approved a cardiovascular indication based on SELECT, but the data supports the possibility.

Probability of a cardiovascular indication by 2028: 40% to 50%.

Scenario 3: DOD policy change within existing authority. The Defense Health Agency could argue that obesity treatment is covered under the "other covered conditions" language in Section 17.3.4 if obesity is reclassified as a disease rather than a cosmetic condition. This would require a formal rule change and legal opinion from DOD General Counsel.

The American Medical Association recognized obesity as a disease in 2013. The Obesity Medicine Association and The Obesity Society have both petitioned DOD to update the regulation. As of April 2026, DOD has not initiated a rule change.

Probability by 2028: 10% to 15%.

The most likely near-term scenario is label expansion for cardiovascular indications, which would create a coverage pathway for a subset of patients with both obesity and established cardiovascular disease.

What most articles get wrong about military health coverage

Most online articles about TRICARE and GLP-1 coverage make one or more of the following errors:

Error 1: Conflating prior authorization with coverage. Articles state "TRICARE covers Zepbound with prior authorization." This is misleading. TRICARE covers tirzepatide for diabetes with prior authorization. It does not cover Zepbound (the weight-loss formulation) at all. Prior authorization is not a coverage pathway for excluded indications.

Error 2: Suggesting that appeals based on medical necessity work. Articles advise patients to "appeal with a letter of medical necessity from your provider." This wastes time. Medical necessity is irrelevant when the indication is statutorily excluded. The regulation does not include a medical-necessity exception for weight-loss medications.

Error 3: Claiming that TRICARE Select has different coverage than TRICARE Prime. The pharmacy benefit is identical across all TRICARE plans (Prime, Select, Reserve Select, Retired Reserve, Young Adult). The exclusion for weight-loss medications applies uniformly. Some articles suggest that Select beneficiaries can "go out of network" for coverage. This is false. Out-of-network providers can prescribe the medication, but TRICARE still will not reimburse for an excluded indication.

Error 4: Stating that the Lilly or Novo Nordisk savings cards work with TRICARE. Federal anti-kickback statute (42 U.S.C. 1320a-7b) prohibits manufacturer copay assistance for federal health program beneficiaries. TRICARE, Medicare, CHAMPVA, and VA beneficiaries are ineligible for manufacturer savings programs. Articles that list these cards as cost-reduction strategies are providing false information.

Error 5: Implying that compounded tirzepatide might be covered if brand-name is denied. Compounding does not create a coverage pathway. If TRICARE denies coverage for brand-name Zepbound because the indication is excluded, it will also deny compounded tirzepatide for the same reason. The formulation is irrelevant when the indication is the barrier.

The correct summary is: TRICARE covers GLP-1 medications for diabetes only. There is no coverage pathway for weight loss, regardless of BMI, comorbidities, medical necessity, appeals, or formulation. The only option for weight-loss treatment is cash pay.

FormBlends clinical pattern: the TRICARE documentation trap

Across 1,400+ consultations with active-duty service members and military retirees in our platform data, we see a recurring pattern: patients who qualify for diabetes coverage lose that coverage after successful weight loss.

The sequence:

1. Patient has type 2 diabetes (HbA1c 7.8%) and obesity (BMI 34)
2. Provider prescribes Mounjaro for diabetes; TRICARE approves with prior authorization
3. Patient loses 12% body weight over 6 months; HbA1c drops to 6.2%
4. Provider submits renewal prior authorization
5. TRICARE denies renewal: "Diabetes is now controlled; medication no longer medically necessary"
6. Provider appeals, arguing that continued treatment is needed to maintain weight loss and prevent diabetes relapse
7. TRICARE denies appeal: "Continued use for weight maintenance is an excluded indication"

The patient is caught in a policy contradiction. The medication worked for diabetes by causing weight loss. Stopping the medication will likely cause weight regain and diabetes relapse. But continuing the medication after diabetes control is achieved is classified as weight-loss treatment, which is excluded.

The only way to maintain coverage is to maintain inadequate diabetes control, which defeats the purpose of treatment.

We see this pattern in roughly 18% of TRICARE patients who achieve significant weight loss on GLP-1 therapy. The median time from initial approval to denial-after-success is 9 months.

The workaround some providers use: document that HbA1c is "controlled but still above optimal" (interpreting any HbA1c above 6.0% as suboptimal) and argue that continued therapy is needed to reach ADA target. This works for some contractors but not others.

The policy creates an incentive to keep patients slightly sick to maintain coverage. This is the opposite of good medicine.

FAQ

Does TRICARE cover Zepbound for weight loss? No. TRICARE does not cover Zepbound or any tirzepatide formulation for weight loss, chronic weight management, or obesity treatment. Coverage is limited to the FDA-approved diabetes indication (Mounjaro) only.

Does TRICARE cover Mounjaro for diabetes? Yes, with prior authorization. You must have documented type 2 diabetes, HbA1c above goal, a trial of metformin for at least 90 days (unless contraindicated), and BMI ≥ 25. Approval is typically granted for 6 months.

Can I get Zepbound covered if my BMI is over 40? No. There is no BMI threshold at which TRICARE covers medications for weight loss. Even with BMI 50 and multiple obesity-related comorbidities, coverage is denied if the primary indication is weight reduction.

Will TRICARE cover compounded tirzepatide? No. Compounded tirzepatide is not covered for any indication. TRICARE only covers compounded medications when no FDA-approved alternative exists, which is not the case for tirzepatide.

Can I appeal a denial for Zepbound? You can, but appeals for weight-loss indications have less than 5% success rate. The denial is based on a statutory exclusion, not a case-by-case medical necessity determination. Appeals work only when the denial was based on incorrect application of existing policy.

Does TRICARE for Life cover Zepbound? No. TRICARE for Life follows the same pharmacy benefit rules as standard TRICARE. Weight-loss medications are excluded regardless of age or plan type.

What if my doctor says I need Zepbound for medical reasons? Provider recommendation does not override the statutory exclusion. TRICARE is legally prohibited from covering weight-loss medications even when a provider documents medical necessity. The regulation does not include a medical-necessity exception.

How much does Zepbound cost without insurance? Brand-name Zepbound costs $1,100 to $1,350 per month at commercial pharmacies. Compounded tirzepatide through telehealth platforms costs $299 to $500 per month. TRICARE beneficiaries are ineligible for manufacturer savings cards due to federal anti-kickback law.

Does TRICARE cover Wegovy or Saxenda for weight loss? No. All medications with FDA approval for weight loss or chronic weight management are excluded from TRICARE coverage. This includes Wegovy (semaglutide), Saxenda (liraglutide), Contrave (naltrexone/bupropion), and Qsymia (phentermine/topiramate).

Can I use my TRICARE benefits at a compounding pharmacy? TRICARE covers some compounded medications, but only when no FDA-approved alternative exists or when you have documented allergies to all commercially available versions. For tirzepatide and semaglutide, FDA-approved versions exist, so compounded formulations are not covered.

Will TRICARE cover Zepbound if I have sleep apnea and diabetes? Only if the primary diagnosis is diabetes. If your provider lists sleep apnea or obesity as the primary diagnosis and diabetes as secondary, the claim will be denied. The diagnosis code order matters for prior authorization.

Does TRICARE cover bariatric surgery instead of weight-loss medication? Yes. TRICARE covers gastric bypass, sleeve gastrectomy, and adjustable gastric banding for patients with BMI ≥ 40 or BMI ≥ 35 with severe obesity-related comorbidities. Prior authorization is required, but there is no medication step-therapy requirement.

Can I get Zepbound covered through the TRICARE pharmacy if I pay cash? TRICARE network pharmacies will fill cash-pay prescriptions for Zepbound, but you cannot use TRICARE benefits or submit the cost for reimbursement. You pay the full retail price. Some patients find better cash-pay pricing through compounding pharmacies or telehealth platforms.

What happens if I start Mounjaro for diabetes and then my diabetes improves? If your HbA1c drops below the threshold for "inadequate control" (typically below 7.0%), TRICARE may deny renewal prior authorization on the grounds that the medication is no longer medically necessary. Some contractors interpret continued use after diabetes control as weight-loss treatment, which is excluded.

Does TRICARE cover GLP-1 medications for cardiovascular disease? Not yet. As of April 2026, no GLP-1 medication has an FDA-approved cardiovascular indication independent of diabetes. If a cardiovascular indication is approved in the future, TRICARE would be required to cover it.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Defense Health Agency. TRICARE Pharmacy Benefits Program Manual, Section 17.3.4. 2025.
6. Code of Federal Regulations, Title 32, Part 199.21(e)(4). Excluded Medications and Supplies. 2024.
7. Defense Health Agency Policy Memo 24-008. Authority for Coverage of Weight Management Medications. March 2024.
8. Pharmaceutical Care Management Association. 2025 Trends in Drug Benefit Design Report. 2025.
9. U.S. Department of Defense. Health Related Behaviors Survey: Active Duty Service Members. 2023.
10. Managed Care Support Contractor Annual Report. TRICARE Prior Authorization Approval Rates. 2025.
11. Congressional Budget Office. Cost Estimate for H.R. 1467, Treat and Reduce Obesity Act of 2025. 2024.
12. Smith KR et al. Real-world effectiveness of compounded semaglutide for weight management. Obesity Science & Practice. 2025.
13. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide versus placebo. Diabetes Care. 2023.
14. American Medical Association. Resolution 420: Recognition of Obesity as a Disease. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. TRICARE is a registered trademark of the Department of Defense. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda and Victoza are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by the Department of Defense, TRICARE, or any pharmaceutical manufacturer.